Evidence map›Paper›PMID 36278940›Full record

ArticleACS infectious diseases2022

Large-Scale Synthesis of Man

Mahesh Neralkar, Bokai Xu, Satoru Horiya, Isaac J Krauss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. ACS central science · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mahesh NeralkarDepartment of Chemistry, Brandeis University, Waltham, Massachusetts 02454, United States.
Bokai XuDepartment of Chemistry, Brandeis University, Waltham, Massachusetts 02454, United States.ORCID 0000-0002-0224-416X
Satoru HoriyaDepartment of Chemistry, Brandeis University, Waltham, Massachusetts 02454, United States.
Isaac J KraussDepartment of Chemistry, Brandeis University, Waltham, Massachusetts 02454, United States.ORCID 0000-0003-0984-4085

Funding

Rational and Combinatorial Design of Immunogens to Elicit 2G12-like AntibodiesR01AI090745 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2010 to 2022
$3.9M
Design of Immunogens to Elicit PGT122 like AntibodiesR01AI113737 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2014 to 2018
$2.2M
Directed Evolution of Zika EDE GlycoantigensR21AI140030 · NIAID · BRANDEIS UNIVERSITY · PI KRAUSS, ISAAC JONATHAN · 2018 to 2019
$453k
NIAID NIH HHS R01 AI090745NIAID NIH HHS R01 AI113737NIAID NIH HHS R21 AI140030
6 · The paper itself

Abstract

Access to homogeneous high-mannose glycans in high-mg quantities is necessary for carbohydrate-based HIV vaccine development research. We have used directed evolution to design highly antigenic oligomannose clusters that are recognized in low-nM affinity by HIV antibodies. Herein we report an optimized large-scale synthesis of Man

Indexed as

HIV-1HIV InfectionsAntibodies, MonoclonalHIV AntibodiesHumansMannansMannosePolysaccharidesAntibodies, MonoclonalHIV AntibodiesMannansMannosemannosyl(9)-N-acetylglucosamine(2)Polysaccharides2G12biolayer interferometrybnAbdirected evolutionglycopeptide synthesisHIV broadly neutralizing antibodiesHIV vaccinesoligosaccharide synthesis

Identifiers

PMID36278940
PMCPMC12016021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.